Journal article

An open-label, parallel-group, randomised controlled trial of antiseptic mouthwash versus antibiotics for oropharyngeal gonorrhoea treatment (OMEGA2)

Eric PF Chow, Kate Maddaford, Jane S Hocking, Catriona S Bradshaw, Rebecca Wigan, Marcus Y Chen, Benjamin P Howden, Deborah A Williamson, Christopher K Fairley



New treatments for oropharyngeal gonorrhoea are required to address rising antimicrobial resistance. We aimed to examine the efficacy of a 14-day course of mouthwash twice daily compared to standard treatment (antibiotic) for the treatment of oropharyngeal gonorrhoea. The OMEGA2 trial was a parallel-group and open-labelled randomised controlled trial among men with untreated oropharyngeal gonorrhoea that was conducted between September 2018 and February 2020 at Melbourne Sexual Health Centre in Australia. Men were randomised to the intervention (rinsing, gargling and spraying mouthwash twice daily for 14 days) or control (standard treatment) arm and followed for 28 days. Participants in both..

View full abstract


Awarded by Australian National Health and Medical Research Council (NHMRC)

Awarded by NHMRC

Funding Acknowledgements

This trial was supported by an Australian National Health and Medical Research Council (NHMRC) Investigator Grant (GNT1172873) and the 2018 Club Melbourne Fellowships (awarded to E.P.F.C.). C.K.F. and C.S.B. are supported by an NHMRC Leadership Investigator Grant (GNT1172900 and GNT1173361, respectively). E.P.F.C. and D.A. W. are supported by an NHMRC Emerging Leadership Investigator Grant (GNT1172873 and GNT1174555, respectively). J. S.H. is supported by an NHMRC Senior Research Fellowship (GNT1136117). B.P.H is supported by an NHMRC Practitioner Fellowship (GNT1105905).